Roche has signed a deal to pay $750 million upfront for Boston-based PathAI, an acquisition by the Swiss pharmaceutical giant to speed up its use of artificial intelligence to help pathologists diagnose disease.
Jonathan Saltzman is a reporter at The Boston Globe, where he covers biotechnology and the life sciences. With a strong focus on health and wellness, pharmaceuticals, and healthcare technology, he has contributed to impactful investigations and stories that highlight critical issues in the medical field. Saltzman has been featured in STAT News and The Boston Globe, and his work has earned him several accolades, including a George Polk Award.
















